A finding that could help Alpha-1 sufferers breathe more easily

Scientists have identified a new mutation in the gene that causes the inherited disease known as Alpha-1 Antitrypsin Deficiency (Alpha-1), which affects roughly one in 2,500 people of European descent.

Alpha-1 can lead to serious lung disease in adults, or disease at any age.

The finding extends understanding of Alpha-1 at the molecular level, potentially leading to new drug development and better diagnostic tools.

Dr Darren Saunders from Sydney's Garvan Institute of Medical Research and Professor Vanessa Hayes, from the J. Craig Venter Institute in San Diego, published their results in the international journal PLOS One, now online.

In healthy people, Alpha-1 Antitrypsin is a molecule, or 'protein', made in the liver then secreted into the blood. It helps keep the lungs healthy by blocking an enzyme that causes tissue breakdown.

The that trigger Alpha-1 disease cause the Alpha-1 Antitrypsin protein to accumulate in the liver, rather than being secreted into the blood. That in turn leads to tissue breakdown in the lungs.

-1 is often first diagnosed as asthma or smoking-related (COPD). Typically, people experience symptoms like shortness of breath, wheezing, recurrent chest colds and allergies. They might also develop unexplained .

"We're interested in the fact that the mutation we've identified occurs in a completely different part of the gene from known mutations, yet it causes the same basic effect – the protein doesn't get secreted from ," said Dr Saunders.

The research is still early stage, as the mutation has been identified in only one patient, and that patient is from a Middle-Eastern background.

"We have yet to establish the mutation's prevalence, and we can't do that until we have the funding to examine a wider population of patients."

"At the basic science level, it's a promising breakthrough because it helps us better understand how the protein misbehaves when it's mutated – and that's very important for drug development, because drugs have to try and minimise, or reverse, molecular damage."

"If the mutation turns out to be prevalent, then its inclusion in diagnostic tests will be important."

add to favorites email to friend print save as pdf

Related Stories

Molecular delivery truck serves gene therapy cocktail

Aug 15, 2011

In a kind of molecular gymnastics, scientists at the University of North Carolina at Chapel Hill School of Medicine have devised a gene therapy cocktail that has the potential to treat some inherited diseases associated with ...

Recommended for you

Study reveals nervous system's role in asthma attacks

Jul 22, 2014

(Medical Xpress)—Asthma is a debilitating condition that kills 250,000 people around the world each year. People with asthma have hyperreactive airways and thickened lung walls obstructed with mucus. During ...

New diagnostic test to distinguish psoriasis from eczema

Jul 10, 2014

In some patients, the chronic inflammatory skin diseases psoriasis and eczema are similar in appearance. Up to now, dermatologists have therefore had to base their decision on which treatment should be selected on their own ...

User comments